查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1836846

胚胎胚胎着床前基因检测市场（按检测类型、检测技术类型、提供的服务和最终用户划分）—2025-2032 年全球预测

Preimplantation Genetic Testing Market by Testing Type, Test Type, Technology Type, Offering, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，胚胎着床前基因检测市场规模将成长至 20.092 亿美元，复合年增长率为 12.55%。

主要市场统计数据
基准年2024年 7.8019亿美元
预计2025年 8.7374亿美元
预测年份：2032年 20.92亿美元
复合年增长率（%） 12.55%

胚胎着床前基因检测的引人注目的方向构成了临床整合、技术成熟和不断变化的相关人员的期望

胚胎着床前基因检测已从辅助生殖的专业辅助手段转变为生殖遗传学和个人化生殖医学的核心组成部分。如今，临床医生、实验室主任和机构领导都重视基因检测，将其视为胚胎选择、降低单基因疾病风险以及优化临床结果的重要组成部分。在监管预期不断变化和支付方态度转变的背景下，实验室和诊所面临越来越大的压力，需要确保诊断准确性、简化工作流程，并向患者和转诊网络证明其临床效用。

技术进步正在缩短週转时间，提高分辨率，并使临床决策更加清晰，同时也为与生物资讯学和电子健康记录的整合开闢了新的途径。同时，患者对透明度、咨询和可近性的期望正在重塑服务提供模式。患者越来越要求清晰地解释检测的范围、局限性以及对生育选择的后续影响。因此，胚胎学家、遗传咨询师、实验室科学家和资讯学专业人员之间的跨职能合作对于提供临床上可靠且符合伦理的检测项目至关重要。

展望未来，相关人员必须专注于将临床证据与营运可扩展性结合。实验室和生殖服务提供者必须协调高通量、可重复检测的需求与个人化患者照护。同时，研究机构和诊断合作伙伴正在扩大其转化研究，以改善变异解读、检验新型检测方法并扩展检测适应症。本介绍为深入评估影响胚胎胚胎着床前基因检测格局的变革性变化奠定了基础。

融合的技术创新、不断发展的临床工作流程和监管改进如何重塑生殖遗传学的检测实践和患者路径

在临床、技术和监管力量融合的推动下，胚胎胚胎着床前基因检测领域正在经历变革性变革。定序准确性和生物资讯学演算法的进步提高了胚胎遗传评估的分辨率，使得对非整倍体、结构重排和单基因变异的检测更加精准。因此，实验室正在从单一方法模式转向将高通量定序与标靶确认检测相结合的混合工作流程，从而在兼顾成本和通量的同时提高诊断可信度。

同时，临床生态系统正在适应患者日益增长的需求，即对全面遗传学洞察和清晰的咨询框架的需求。遗传咨询已成为病人历程就诊体验的核心，有助于做出明智的决策并进行风险沟通。同时，支付方和医疗系统开始更严格地审查临床价值提案，鼓励医疗服务提供者收集结果数据并展示其检测策略的实际效用。监管机构也在加强审查力度，提高对分析和临床验证、实验室认证以及诊断检测上市后监管的期望。

在营运方面，供应链弹性和试剂标准化已成为实验室规划的重中之重，推动了库存管理和多元化采购的投资。在更高层面，生育诊所、诊断实验室和专业软体提供者之间的策略联盟正在加速发展，以创造出将实验室服务与分析、报告和病人参与结合的垂直整合解决方案。这些转型正在全面重塑检测的交付方式、报销方式以及患者和临床医生的认知。

评估 2025 年关税上调对诊断和生育服务提供者的供应链、筹资策略和营运弹性的系统性影响

2025年推出的高关税措施和贸易限制措施，增加了对支撑基因检测工作流程的跨国供应链的审查。进口附加税和累积关税调整增加了专用设备、试剂和耗材的到岸成本，给依赖国际供应商的诊断实验室和生育中心带来了直接的财务压力。因此，许多机构正在重新审视筹资策略，优先选择拥有强大本地分销网络和替代采购管道的供应商，以减轻关税波动的影响。

这些贸易动态对资本投资和服务交付产生了连锁影响。考虑购买新设备的医疗保健机构不仅考虑购买价格，还考虑长期维护、备件供应和试剂采购风险。因此，采购週期不断延长，资本配置决策也优先考虑总拥有成本透明且物流弹性强的供应商。一些机构也正在加速整合区域网路采购，并签订长期供应协议，以稳定价格和供应。

除了采购之外，关税也重新激发了人们对近岸外包和区域製造伙伴关係的兴趣。相关人员正在评估本地化组件组装和试剂生产的机会，以减少进口关税的影响并缩短补货交付前置作业时间。同时，实验室正在投资于流程优化和检测稳健性，以减少对单一来源试剂的依赖。简言之，2025年关税变动的累积影响更重视供应链敏捷性、本地伙伴关係发展与采购管治，并将其视为营运韧性的基本要素。

将测试类别、调查方法平台、行销产品和最终用户采用模式与策略重点连结起来的详细细分洞察

細項分析揭示了检测类型、检测格式、技术、产品和最终用户之间不同的临床和商业性动态。根据检测类型，用于非整倍体检测的 PGT-A、用于单基因疾病的 PGT-M 和用于结构重排的 PGT-SR 之间的差异凸显了不同的实验室工作流程、咨询需求和证据标准。例如，PGT-M 计画通常需要密集的家族特异性检测开发和深度的临床基因整合，而 PGT-A 工作流程则优先考虑高通量非整倍体筛检和简化的报告流程。根据检测类型胚胎着床前遗传学诊断与胚胎着床前遗传学筛检分开来，凸显了临床意图和患者咨询的差异。诊断通常侧重于已知的遗传性突变并提供有针对性的解读，而筛检强调更广泛的染色体评估和人群层面的风险分层。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用非侵入性胚胎检测技术，透过废培养基分析来改善基因筛检结果
  • 整合人工智慧和机器学习演算法，实现胚胎着床前测试中的自动化胚胎评估
  • 扩大单基因和多基因疾病的胚胎着床前基因检测，以支持个人化生殖计划
  • 可携式次世代定序平台的出现，使得快速且经济高效的胚胎着床前遗传分析成为可能
  • 不断发展的伦理准则和法律规范正在塑造胚胎着床前基因检测实践的全球标准
  • 远端医疗遗传咨询的需求正在增加，以改善偏远地区获得胚胎着床前检测服务的机会
  • 生育诊所与生技公司建立策略伙伴关係，加速胚胎胚胎着床前基因检测创新
  • 全基因组定序成本的降低将增加综合胚胎着床前筛检解决方案的采用
  • 人们对透过数位生育平台直接面向消费者的胚胎着床前基因筛检服务的兴趣日益浓厚
  • 关注健康公平倡议，扩大医疗服务涵盖缺医少药族群

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章胚胎着床前基因检测市场（依检测类型）

  • PGT-A（非整倍体）
  • PGT-M（单基因疾病）
  • PGT-SR（结构重建）

第九章：胚胎胚胎着床前基因检测市场（依检测类型）

  • 胚胎着床前基因诊断
  • 胚胎胚胎着床前基因筛检

第 10 章 胚胎胚胎着床前基因检测市场（依技术类型）

  • 比较基因组杂合反应
  • 萤光原位杂合技术
  • 次世代定序
  • PCR检测
  • 单核苷酸多态性

第 11 章 胚胎胚胎着床前基因检测市场（依产品提供）

  • 装置
  • 试剂和耗材
  • 软体

第十二章 胚胎胚胎着床前基因检测市场（依最终用户划分）

  • 诊断实验室
  • 不孕不育诊所
  • 医院
  • 研究机构

第十三章 胚胎胚胎着床前基因检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章胚胎着床前基因检测市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国胚胎胚胎着床前基因检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Bio-Techne Corporation
    • Bioarray SL
    • EUROPE IVF International sro
    • F. Hoffmann-La Roche AG
    • Genea Limited
    • GENETiKS
    • Illumina, Inc.
    • Invicta Genetics
    • Invitae Corporation
    • Juno Genetics, US Inc.
    • Laboratory Corporation of America Holdings
    • MedGenome Labs Ltd.
    • Merck KGaA
    • Natera, Inc.
    • NextGen Genetics Holdings, LLC
    • Ovation Fertility
    • PacGenomics
    • PerkinElmer, Inc.
    • Progyny, Inc.
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • Reproductive Genetic Innovations, LLC
    • SEQUENCE46, LLC
    • Sysmex Corporation
    • Takara Bio Inc.
    • The Cooper Companies Inc.
    • Thermo Fisher Scientific Inc.
    • Vitrolife Sweden AB
    • Yikon Genomics（Shanghai）Co., Ltd.
Product Code: MRR-030EE48515DA

The Preimplantation Genetic Testing Market is projected to grow by USD 2,009.20 million at a CAGR of 12.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 780.19 million
Estimated Year [2025] USD 873.74 million
Forecast Year [2032] USD 2,009.20 million
CAGR (%) 12.55%

A compelling orientation to preimplantation genetic testing that frames clinical integration, technological maturation, and evolving stakeholder expectations

Preimplantation genetic testing has moved from a specialized adjunct to assisted reproduction into a core element of reproductive genetics and personalized reproductive care. Clinicians, laboratory directors, and institutional leaders now evaluate genetic testing as an integral part of embryo selection, risk mitigation for monogenic disorders, and optimizing clinical outcomes. Against a backdrop of evolving regulatory expectations and shifting payer attitudes, laboratories and clinics face heightened pressure to ensure diagnostic accuracy, streamline workflows, and demonstrate clinical utility to both patients and referral networks.

Technological progress has compressed turnaround times and improved resolution, enabling more definitive clinical decision-making while opening new pathways for integration with bioinformatics and electronic health records. Concurrently, patient expectations around transparency, counseling, and access are reshaping service delivery models; patients increasingly demand clear explanations of test scope, limitations, and the downstream implications for reproductive choices. As a result, cross-functional collaboration among embryologists, genetic counselors, laboratory scientists, and informatics specialists has become essential for delivering clinically robust and ethically sound testing programs.

Looking ahead, stakeholder imperatives center on harmonizing clinical evidence with operational scalability. Laboratories and fertility providers must reconcile the need for high-throughput, reproducible assays with individualized patient care. At the same time, research institutions and diagnostic partners are expanding translational efforts to refine variant interpretation, validate novel assays, and expand testing indications. This introduction sets the stage for a deeper appraisal of the transformative shifts reshaping the preimplantation genetic testing landscape.

How converging technological innovations, evolving clinical workflows, and regulatory refinements are reshaping testing operations and patient pathways in reproductive genetics

The preimplantation genetic testing environment is undergoing transformative shifts driven by converging clinical, technological, and regulatory forces. Advances in sequencing accuracy and bioinformatic algorithms have increased the resolution of embryo genetic assessment, enabling more nuanced detection of aneuploidy, structural rearrangements, and single-gene variants. Consequently, laboratories are transitioning from single-method paradigms to hybrid workflows that combine high-throughput sequencing with targeted confirmatory assays, thereby improving diagnostic confidence while managing cost and throughput considerations.

Simultaneously, the clinical ecosystem is adapting to greater patient demand for comprehensive genetic insight coupled with clear counseling frameworks. Genetic counseling has become more central to the patient journey, facilitating informed decision-making and risk communication. In parallel, payers and health systems are beginning to scrutinize clinical value propositions more closely, which is prompting providers to collect outcomes data and demonstrate the real-world utility of testing strategies. Regulatory authorities are also refining oversight, with increased expectations for analytical and clinical validation, laboratory accreditation, and post-market surveillance of diagnostic assays.

Operationally, supply chain resilience and reagent standardization have moved to the forefront of laboratory planning, prompting investments in inventory management and diversified sourcing. At a higher level, strategic alliances between fertility clinics, diagnostic laboratories, and specialist software providers are accelerating to create vertically integrated solutions that combine laboratory services with analytics, reporting, and patient engagement. These transformative shifts are collectively reshaping how testing is delivered, reimbursed, and perceived by patients and clinicians alike.

Assessing the systemic consequences of 2025 tariff changes on supply chains, procurement strategies, and operational resilience across diagnostic and fertility providers

The introduction of elevated tariff measures and trade restrictions in 2025 has intensified scrutiny of cross-border supply chains that support genetic testing workflows. Import levies and cumulative tariff adjustments have increased landed costs for specialized instruments, reagents, and consumables, creating immediate operational pressure for diagnostic laboratories and fertility centers that depend on international suppliers. In response, many organizations have re-evaluated procurement strategies to prioritize suppliers with robust local distribution networks or alternative sourcing channels that mitigate exposure to tariff volatility.

These trade dynamics have cascading implications for capital investment and service delivery. Institutions contemplating new instrument acquisitions are weighing not only acquisition price but also long-term maintenance, spare parts availability, and reagent procurement risk. As a result, procurement cycles have elongated and capital allocation decisions have been re-prioritized to favor suppliers with transparent total cost of ownership and resilient logistics. Some providers have also accelerated efforts to aggregate purchasing across regional networks or enter into long-term supply agreements to stabilize pricing and availability.

Beyond procurement, tariffs have spurred renewed interest in nearshoring and regional manufacturing partnerships. Stakeholders are evaluating opportunities to localize component assembly or reagent production to reduce exposure to import duties and expedite replenishment lead times. At the same time, laboratories are investing in process optimization and assay robustness to reduce dependency on single-source reagents. In short, the cumulative impact of tariff changes in 2025 has heightened emphasis on supply chain agility, local partnership development, and procurement governance as fundamental elements of operational resilience.

In-depth segmentation insights that connect testing categories, methodological platforms, commercial offerings, and end-user adoption patterns to strategic priorities

Segmentation analysis reveals differentiated clinical and commercial dynamics across testing types, test formats, technologies, offerings, and end users. Based on testing type, distinctions among PGT-A for aneuploidy detection, PGT-M for monogenic disorders, and PGT-SR for structural rearrangements highlight divergent laboratory workflows, counseling needs, and evidentiary standards; for example, PGT-M programs often require intensive family-specific assay development and deep clinical-genetic integration, whereas PGT-A workflows prioritize high-throughput aneuploidy screening and streamlined reporting. Based on test type, the separation between preimplantation genetic diagnosis and preimplantation genetic screening underscores differences in clinical intent and patient counseling; diagnosis is typically focused on known familial variants and targeted interpretation, while screening emphasizes broader chromosomal assessment and population-level risk stratification.

Based on technology type, the competitive dynamics hinge on methodological trade-offs among comparative genomic hybridization, fluorescent in-situ hybridization, next-generation sequencing, PCR-based testing, and single-nucleotide polymorphism arrays. Next-generation sequencing is increasingly favored for its scalability and resolution, yet PCR-based and SNP approaches retain roles in confirmatory testing and specific assay designs. Comparative genomic hybridization and FISH continue to be relevant for certain structural assessments and regulatory-validated workflows, especially where orthogonal confirmation is required. Based on offering, the ecosystem separates into instruments, reagents and consumables, and software; instruments drive capital expenditure and laboratory footprint decisions, reagents and consumables determine recurring operating costs and supply chain exposure, and software governs data interpretation, reporting, and integration with clinical systems. Based on end user, diagnostic laboratories, fertility clinics, hospitals, and research institutes exhibit variable adoption patterns; diagnostic laboratories prioritize standardized, high-throughput workflows and accreditation, fertility clinics focus on turnaround time and counseling integration, hospitals emphasize interdisciplinary coordination and inpatient pathways, and research institutes prioritize methodological innovation and validation pathways. Together, these segmentation lenses illuminate where clinical needs, operational constraints, and commercial opportunities intersect, enabling stakeholders to prioritize investments and partnerships aligned with their strategic capabilities.

How regional regulatory frameworks, payer environments, and clinical adoption patterns are shaping differentiated strategies in the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape both service delivery models and strategic partnerships across the preimplantation genetic testing landscape. Americas maintain a combination of advanced clinical adoption in major urban centers and rapid innovation diffusion through private fertility networks, which has led to a dense ecosystem of specialized laboratories, referral clinics, and academic collaborators. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory frameworks and payer models; pockets of highly advanced public and private centers coexist with regions where access is constrained, driving cross-border patient mobility and centralized laboratory services. This regional heterogeneity encourages pan-regional laboratory networks and standardized reporting approaches to address cross-jurisdictional clinical needs.

Asia-Pacific exhibits heterogenous trajectories as well, with select markets demonstrating rapid scale-up of assisted reproductive services, strong private-sector investment, and increased local capability in genomics. At the same time, several markets in the region are investing in capacity-building and regulatory frameworks to support clinical validation and ethical oversight. Across all regions, differences in reimbursement landscapes, regulatory expectations, and cultural perspectives on reproductive genetics influence service models, patient counseling practices, and commercialization strategies. As a result, successful regional approaches blend localized clinical pathways with global best practices in quality management and evidence generation, enabling providers to deliver consistent, ethically grounded, and operationally sustainable testing services.

Corporate strategies and partnership dynamics revealing how integration, specialization, and collaboration are redefining competitive advantage across diagnostics and service providers

Company-level dynamics in the preimplantation genetic testing space reflect a mix of vertical integration, strategic specialization, and collaborative ecosystems. Some organizations have concentrated on end-to-end solutions that combine instrumentation, reagents, and interpretive software to deliver turnkey offerings for fertility clinics and centralized laboratories. Other players have focused on niche strengths such as assay development for rare monogenic disorders, high-resolution structural variant detection, or cloud-native analytics for variant interpretation and reporting. In parallel, laboratory service providers have expanded clinical partnerships and referral networks to offer outsourced testing with standardized quality controls and consolidated reporting frameworks.

Partnerships and alliance formation have emerged as a primary vector for capability expansion. Commercial agreements between diagnostic laboratories and fertility networks, as well as collaborations with software vendors for integrated reporting, have enabled faster market entry and reduced the need for duplicative capital investment. In addition, strategic investments in regulatory compliance and accreditation have become competitive differentiators for laboratories seeking to serve international referral markets. Mergers and acquisitions continue to reconfigure the competitive terrain, especially where scale affords supply chain leverage, broader test menus, and enhanced data assets for variant curation. Collectively, these company insights underscore the importance of aligning technical capabilities with clear commercial pathways and compliance infrastructure to sustain growth and clinical credibility.

Practical, high-impact strategies that industry stakeholders can implement to enhance evidence generation, supply chain resilience, informatics integration, and patient-centered service delivery

Industry leaders can take decisive actions to strengthen clinical relevance, operational resilience, and commercial differentiation. First, prioritize investment in assay validation and clinical evidence that demonstrate real-world utility across diverse patient cohorts and clinical pathways; such evidence supports stronger clinician adoption and more effective communication of value to payers and institutional buyers. Second, cultivate resilient supply chains through multi-source procurement, regional distributor partnerships, and inventory strategies that mitigate exposure to tariff-driven or geopolitical disruptions. By emphasizing transparent total cost of ownership and predictable replenishment, organizations can reduce service interruptions and protect margins.

Third, accelerate integration of robust bioinformatics and interpretive software to standardize reporting, improve turnaround time, and enhance variant curation workflows. Interoperability with electronic health records and laboratory information systems will be a significant factor in clinician acceptance and cross-disciplinary coordination. Fourth, embed genetic counseling into the patient pathway to ensure informed consent, appropriate expectation-setting, and patient-centered communication about test scope and limitations. Finally, pursue strategic alliances and partnership models that combine clinical expertise, laboratory scale, and data analytics to unlock synergies while preserving regulatory compliance. These actions, when implemented in concert, create a defensible position that addresses both near-term operational risks and longer-term strategic growth.

Transparent and rigorous research methodology combining primary expert interviews, secondary evidence synthesis, and iterative validation to ensure robust and actionable insights

The research methodology underpinning this analysis blends primary expert engagement with structured secondary synthesis and iterative validation. Primary research included in-depth interviews with clinical laboratory leaders, embryologists, genetic counselors, procurement officers, and regulatory specialists to capture operational realities, clinical decision drivers, and procurement constraints. These qualitative insights were complemented by technical assessments of prevailing assay methodologies, analytical performance characteristics, and workflow integration challenges, drawing on peer-reviewed literature and technical white papers to ensure methodological rigor.

Secondary synthesis involved systematic review of clinical guidelines, professional society statements, and regulatory advisories to align the analysis with current standards of practice and compliance expectations. Data triangulation was used to reconcile divergent inputs and to surface consistent patterns across respondent groups and documented sources. Finally, findings underwent internal peer review and scenario stress-testing to evaluate sensitivity to supply chain disruptions, tariff variations, and technology adoption trajectories. The combined methodology ensures that conclusions are grounded in both frontline operational experience and documented best practices, providing a reliable basis for decision-making and strategic planning.

A definitive synthesis of the strategic imperatives, operational challenges, and clinical enablers that will determine sustainable adoption and long-term integration of genetic testing in reproductive care

In synthesis, preimplantation genetic testing stands at an inflection point where technological maturation, patient expectations, and operational realities converge to reshape service delivery. Laboratories and fertility providers must balance the need for high analytical performance with scalable workflows and resilient supply chains. The evolving regulatory environment and payer scrutiny will reward organizations that prioritize rigorous validation, clear clinical evidence, and demonstrable quality controls. At the same time, investments in bioinformatics, interpretive software, and integrated counseling pathways will be decisive in delivering patient-centered care and supporting clinician adoption.

Strategically, stakeholders that pursue collaborative models-combining laboratory excellence, clinical partnerships, and software-enabled reporting-are best positioned to translate technical capability into sustainable clinical services. Moreover, pragmatic procurement and regional partnership strategies will mitigate exposure to trade disruptions and tariff-related cost pressures. Looking forward, the sector's ability to standardize quality metrics, improve variant interpretation, and communicate clinical utility effectively will determine its broader acceptance and long-term integration into reproductive health practice. These conclusions underscore the imperative for coordinated action across clinical, operational, and commercial domains to realize the full potential of preimplantation genetic testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of noninvasive embryo testing techniques through spent culture media analysis for improved genetic screening outcomes
  • 5.2. Integration of artificial intelligence and machine learning algorithms for automated embryo evaluation in preimplantation testing
  • 5.3. Expansion of preimplantation genetic testing for monogenic and polygenic disorders to support personalized reproductive planning
  • 5.4. Emergence of portable next-generation sequencing platforms enabling rapid and cost-effective preimplantation genetic analysis
  • 5.5. Evolving ethical guidelines and regulatory frameworks shaping global standards for preimplantation genetic testing practice
  • 5.6. Growing demand for telehealth-enabled genetic consultations to enhance access to preimplantation testing services in remote regions
  • 5.7. Strategic partnerships between fertility clinics and biotechnology firms to accelerate innovation in preimplantation genetic testing
  • 5.8. Increasing affordability of whole genome sequencing driving broader adoption of comprehensive preimplantation screening solutions
  • 5.9. Rising interest in direct-to-consumer preimplantation genetic screening offerings through digital fertility platforms
  • 5.10. Focus on health equity initiatives to expand preimplantation genetic testing availability in underserved populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preimplantation Genetic Testing Market, by Testing Type

  • 8.1. PGT-A (Aneuploidy)
  • 8.2. PGT-M (Monogenic Disorders)
  • 8.3. PGT-SR (Structural Rearrangements)

9. Preimplantation Genetic Testing Market, by Test Type

  • 9.1. Preimplantation Genetic Diagnosis
  • 9.2. Preimplantation Genetic Screening

10. Preimplantation Genetic Testing Market, by Technology Type

  • 10.1. Comparative Genomic Hybridization
  • 10.2. Fluorescent In-Situ Hybridization
  • 10.3. Next-Generation Sequencing
  • 10.4. PCR-Based Testing
  • 10.5. Single-Nucleotide Polymorphism

11. Preimplantation Genetic Testing Market, by Offering

  • 11.1. Instruments
  • 11.2. Reagents & Consumables
  • 11.3. Software

12. Preimplantation Genetic Testing Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Fertility Clinics
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Preimplantation Genetic Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Preimplantation Genetic Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Preimplantation Genetic Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Agilent Technologies, Inc.
    • 16.3.3. Bio-Techne Corporation
    • 16.3.4. Bioarray S.L.
    • 16.3.5. EUROPE IVF International s.r.o.
    • 16.3.6. F. Hoffmann-La Roche AG
    • 16.3.7. Genea Limited
    • 16.3.8. GENETiKS
    • 16.3.9. Illumina, Inc.
    • 16.3.10. Invicta Genetics
    • 16.3.11. Invitae Corporation
    • 16.3.12. Juno Genetics, US Inc.
    • 16.3.13. Laboratory Corporation of America Holdings
    • 16.3.14. MedGenome Labs Ltd.
    • 16.3.15. Merck KGaA
    • 16.3.16. Natera, Inc.
    • 16.3.17. NextGen Genetics Holdings, LLC
    • 16.3.18. Ovation Fertility
    • 16.3.19. PacGenomics
    • 16.3.20. PerkinElmer, Inc.
    • 16.3.21. Progyny, Inc.
    • 16.3.22. Qiagen N.V.
    • 16.3.23. Quest Diagnostics Incorporated
    • 16.3.24. Reproductive Genetic Innovations, LLC
    • 16.3.25. SEQUENCE46, LLC
    • 16.3.26. Sysmex Corporation
    • 16.3.27. Takara Bio Inc.
    • 16.3.28. The Cooper Companies Inc.
    • 16.3.29. Thermo Fisher Scientific Inc.
    • 16.3.30. Vitrolife Sweden AB
    • 16.3.31. Yikon Genomics (Shanghai) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-A (ANEUPLOIDY), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-M (MONOGENIC DISORDERS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PGT-SR (STRUCTURAL REARRANGEMENTS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENT IN-SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 238. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 239. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. GCC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 274. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 275. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. G7 PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 286. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 287. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. NATO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TESTING TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025-2032